The Cannamonitor Monthly Brief
The whole cannabis market, month by month.
Once a month we read every market that moved — the regulators, the operators and the science — and write it up in one place, with every claim linked back to the document it came from. You can get the summary free by email, or read the full brief in Essentials the moment it is written.
3,500+readers
420+sources tracked
50+markets covered
30+editions since July 2023
Get the brief by email
Free. The summary of each edition, once a month. Unsubscribe from any edition.
Want the full brief straight away? See Essentials →
The Cannamonitor Monthly Brief
The whole cannabis market, month by month.
Once a month we read every market that moved — the regulators, the operators and the science — and write it up in one place, with every claim linked back to the document it came from. Free to read here. Subscribers get each edition first, in full, inside the platform.
3,500+readers
420+sources tracked
50+markets covered
30+editions since July 2023
Latest public edition
The most recent brief, free to read.
This is the public edition. The full brief lives in Essentials.Free subscribers get a summary by email each month. Essentials members read the full brief the moment it is written, with every country section, its sources and the regulation and market databases behind it.
A newer edition is already out — subscribers are reading it now.Every brief goes to subscribers the moment it is written. The public edition below is the most recent one released here; the current edition follows a few weeks later.
What's inside
How every edition reads.
Each brief follows the same order, so you can find what matters to you in a minute and then go as deep as you need.
In every edition
- 1The month in three linesRegulation, market and science, a paragraph each, so you have the month in two minutes.
- 2Ten key figuresThe numbers of the month, each one with its country and exactly what it counts.
- 3New analysisThe market reads we published that month, with the data behind them.
- 4Tracker updateWhat we added to the regulatory, clinical, earnings, deals and product trackers.
- 5Country by countryEach market opens with what is on the radar, then its regulation, market and science, with every line linked to its source.
Every market, read three ways
🏛️
RegulationWhat changed in law, licensing and enforcement, traced back to the official text, and where the reform is heading next.
💼
MarketImports, prescriptions, sales, pricing, deals and company results, read against the market and not against the press release.
🔬
ScienceThe trials and publications that shift the clinical picture: what a finding actually supports, and what it does not.
What's inside
Three lenses on every market.
Every market in every edition is read three ways — the same taxonomy that runs through the whole Cannamonitor platform.
🏛️Regulation
- ⚖️Laws & rulingswhat changed in licensing and enforcement, and what it does to access
- 📜Bills & consultationstraced back to the official text, not the press release
- 🧭Directionwhere the reform is heading next, not only where it landed
💼Business
- 📈Market dataimports, prescriptions, sales and pricing, month over month
- 🏢Companiesresults read against the market, and who gained or lost share
- 💰Deals & capitalM&A, licensing, funding and market entry — and at what price
🔬Science
- 🧪Trialswhat started, stopped or reported out, and on what endpoint
- 🔎Evidencewhat a finding actually supports — and what it does not
- ⚗️Productsformulation and delivery trends emerging behind the data
2026 so far
The stories that have shaped 2026.
Nine editions in, these are the threads that kept coming back. Every line comes from the brief of that month, and each month takes you to the edition it came from.
The year in eight numbers
🇩🇪 Germany201 timported in 2025, +176% on the yearFeb edition🇺🇸 United StatesUS$3.55bnstate cannabis excise receipts in the year to June 2026Sep edition🇨🇦 CanadaC$517.8mrecord monthly retail sales, set in JuneAug edition🇧🇷 Brazil1M+patients, on an R$470m first halfAug edition🇬🇧 United Kingdom1.7Mitems dispensed in 2025Aug edition🇮🇱 Israel143,900patients, a recordJul edition🇵🇹 Portugal66.3 texported in the first half, against 80 t in all of 2025Aug edition🇩🇰 Denmark22,410pilot prescriptions, a recordSep edition
Six stories, month by month
Swipe to read all six →
Drawn from the January to September 2026 editions of the Monthly Brief.
Anatomy of an edition
Every market, read three ways.
Each market in the edition gets its own section, split regulation · business · science. Pick a market to read what its section actually said — every line links the document it came from.
🇺🇸USA
🇺🇸USA
- RegulationThe DEA told its rescheduling hearing on 29 June that the government “supports” the proposed reclassification, not merely proposes it.
- MarketTrulieve listed as TRLV on 10 June, the first plant-touching US operator to trade on the NYSE.
- ScienceA retrospective cohort of 1,946 PTSD patients linked medical cannabis to 35.6% fewer urgent-care and 35.1% fewer emergency visits.
🇩🇪Germany
🇩🇪Germany
- RegulationA draft bill reached its Bundestag hearing on 22 June, seeking to strip dried flower from statutory reimbursement under §31(6) SGB V.
- MarketExilby’s authorisation opens a near-€400m reimbursed opportunity, with Krautinvest modelling €387m a year across 10m chronic-back-pain patients.
- ScienceGermany granted Europe’s first authorisation for a cannabis-derived non-opioid painkiller, with Exilby cleared on 9 June on 1,200+ Phase III patients.
🇨🇦Canada
🇨🇦Canada
- RegulationOntario’s AGCO found SNDL held de facto control of 46 cannabis stores, against a provincial 25% producer-ownership cap.
- MarketPre-rolls overtook flower as Canada’s largest cannabis category at C$1.43bn and 34% share in 2025.
- ScienceA Canadian N-of-1 trial across eight cancer centres found 50 of 89 participants improved versus placebo on medical cannabis extracts.
🇧🇷Brazil
🇧🇷Brazil
- RegulationANVISA let compounding pharmacies produce derivatives under a revised RDC 327, opening a domestic manufacturing route.
- MarketImport demand hit a record, with March import permits reaching 23,199 — up 60.1% year on year — and 61,000+ authorisations in Q1 2026.
🇦🇺Australia
🇦🇺Australia
- RegulationThe TGA tightened medicinal-cannabis advertising rules, closing the clinic-to-prescription funnels and ‘wellness’ branding loophole.
- MarketLittle Green Pharma completed its merger with Cannatrek, as consolidation accelerates at the top of a tightening market.
- ScienceA Sydney-led randomised trial found oral CBD at 800 mg/day reduced spinal-cord-injury pain against placebo.
🇹🇭Thailand
🇹🇭Thailand
- RegulationThe House Public Health Committee opened a formal review of whether cannabis should return to the narcotics list, urged on by an anti-drug network.
- MarketThe government moved cannabis export filings onto a digital platform, formalising the export channel as domestic policy tightens.
- ScienceKing Chulalongkorn Memorial Hospital tested cannabis oil during breast-cancer chemotherapy in a ten-woman randomised pilot.
🇬🇧UK
🇬🇧UK
- RegulationThe FSA is set to hand CBD novel-food authorisations to the EU under SPS realignment, leaving 12,000+ products in limbo.
- MarketA market report projects more than 140,000 UK patients in 2026, with SKUs up from 374 to 818 and flower averaging £6.80/g.
- ScienceUniversity of Bath researchers tied commercial legalisation to higher use in a Lancet Psychiatry review spanning 2000–2025.
🇫🇷France
🇫🇷France
- RegulationThe health minister told AFP the regulatory texts are due in July, finally putting a date on medical-cannabis generalisation.
- ScienceFrance’s first real-world study found medical cannabis reduced painkiller use, most clearly in refractory neuropathic pain.
🇳🇱Netherlands
🇳🇱Netherlands
- RegulationDutch parties pressed the cabinet on whether the tobacco deal could be blocked, with a Bibob integrity review still pending.
- MarketVillage Farms started cultivation at its Groningen facility after receiving final approvals.
🇮🇱Israel
🇮🇱Israel
- RegulationThe Commissioner of Trade Levies launched a second anti-dumping investigation into Canadian imports, months after the first was buried.
- MarketIM Cannabis and InterCure both raised fresh capital in June, underlining the financial triage among Israel’s listed operators.
- ScienceAn Israeli oncology cohort tied non-adherence to patient profile rather than to whether the drug worked.
🇵🇹Portugal
🇵🇹Portugal
- RegulationOperation Erva Daninha widened from a criminal case into a challenge to the credibility of Portugal’s medical-cannabis regime.
- MarketCuraleaf Laboratories and Herdade das Barrocas partnered to reintroduce HDB products to the UK, pairing Portuguese cultivation with UK manufacturing.
🇺🇦Ukraine
🇺🇦Ukraine
- MarketThe first patients in Vinnytsia received cannabis-based medicines, the first real-world use of Ukraine’s e-prescription system.
🇵🇱Poland
🇵🇱Poland
- RegulationThe Ministry of Health’s draft Prescription Act would restrict teleconsultation prescribing, threatening the channel that made the market scalable.
- MarketPanaceum Cannmed launched an EU-GMP production project in Częstochowa, seeking PLN 10 million to build a vertically integrated platform.
🇪🇸Spain
🇪🇸Spain
- RegulationA Cannabis Club Systems / Nefos breach exposed roughly 985,000 member IDs and consumption data through insecure public URLs.
- MarketLinneo Health expanded its extract portfolio into THC and CBD APIs, standardised extracts and dronabinol.
- ScienceA Spanish study tested CBD and CBG in edible coatings on strawberries, reporting shelf-life gains and antibacterial activity at 2–4 µg/mL.
🇦🇷Argentina
🇦🇷Argentina
- RegulationNeuquén prosecutor José Gerez questioned doctors linked to mass REPROCANN registrations, alleging authorised grows were diverting to the illicit market.
- MarketCannava signed a strategic deal with NOC PHARMA to export medical-cannabis granulate, alongside a renewed inflorescence-supply agreement.
🇨🇭Switzerland
🇨🇭Switzerland
- RegulationThe Green Liberal Party filed postulate 26.3958, asking the National Council to assess whether wider medical access would cut healthcare costs.
- MarketThe CanLeg pilot in St. Gallen won federal approval, adding another large-scale recreational-access trial to the Swiss landscape.
🇳🇿New Zealand
🇳🇿New Zealand
- MarketOra Pharm bought Helius Therapeutics out of administration, creating New Zealand’s largest medical-cannabis company.
🇮🇪Ireland
🇮🇪Ireland
- RegulationThe Oireachtas Joint Committee on Drugs Use recommended full decriminalisation of possession, urging repeal of Section 3 of the 1977 Act.
- MarketDunbar Pharma’s CEO said Ireland can scale cannabinoid medicines on its EU-GMP base, but lacks access pathways and patient capital.
🇪🇺EU
🇪🇺EU
- RegulationThe UK–EU SPS reset shifts responsibility for CBD novel-food pathways back to Brussels, leaving 12,000+ products tied to UK applications uncertain.
- ScienceA major review warned climate change threatens Europe’s hemp and flax fibre base, making resilience a competitiveness issue for the sector.
🇮🇹Italy
🇮🇹Italy
- RegulationTAR Liguria suspended a municipal closure order in Ventimiglia, the first administrative-law pushback against Article 18 of the Decreto Sicurezza.
🇿🇦South Africa
🇿🇦South Africa
- RegulationGareth Prince’s Western Cape High Court bid to halt cannabis arrests was delayed on 8 June on procedural grounds, with the next hearing set for 31 July.
- MarketThe Free State government backed entrepreneur Molihobeng Semela, whose company is scaling from cosmetics into cultivation and processing.
- ScienceThe University of Johannesburg unveiled a hemp-brick prototype with Canna-B-Africa, aimed at low-cost, carbon-negative housing.
🇲🇦Morocco
🇲🇦Morocco
- RegulationANRAC said Morocco’s framework is ready and its therapeutic offer available, while describing actual therapeutic use as still “timid”.
- MarketMoroccocanna launched a Moroccan CBD cosmetics range, extending from cultivation into consumer hemp-derived beauty products.
🇺🇾Uruguay
🇺🇾Uruguay
- RegulationThe Technical Advisory Committee on Therapeutic Cannabis filed a third petition to add medical cannabis to the national medicines list.
- MarketGreenMed is accelerating its Latin American expansion with Brazil as its primary target, the region’s largest near-term market.
🇬🇷Greece
🇬🇷Greece
- RegulationGreek teen cannabis use reached a 25-year high, with 11.5% of 16-year-olds reporting use in the European Drug Report 2026.
- ScienceA 30-day Greek pilot tested a cannabinoid face serum on 16 volunteers, reporting improved skin hydration.
🇨🇿Czech Republic
🇨🇿Czech Republic
- RegulationA cross-border patient coalition appealed against the CBD precursor plan hours before the Council for Addiction Policy met on 17 June.
🇮🇳India
🇮🇳India
- RegulationA Delhi High Court timeline pushed the Centre on NDPS reform, lifting cannabis from a state curiosity to a federal-policy question.
- MarketHimachal Pradesh framed hemp as a value chain worth a projected ₹500–2,000 crore a year, shifting the debate to capturing downstream value.
🇯🇵Japan
🇯🇵Japan
- RegulationJapan’s ban on CBN took effect on 1 June, prohibiting possession, sale and import of CBN gummies, oils and vapes.
🇱🇺Luxembourg
🇱🇺Luxembourg
- RegulationLuxembourg’s national drug report found cannabis the most-used drug at roughly 15% past-year prevalence, with THC potency still rising.
🇨🇾Cyprus
🇨🇾Cyprus
- RegulationThe State General Chemistry Office referred CBD stores for possible closure after 88% of 277 sampled products tested as mislabelled.
🇲🇹Malta
🇲🇹Malta
- RegulationARUC will not act on anonymous odour complaints, focusing enforcement on grave, named cases.
🇷🇸Serbia
🇷🇸Serbia
- ScienceNovi Sad researchers tested hemp on contaminated dredged sediment, finding phytostabilisation rather than strong metal extraction.
🇹🇼Taiwan
🇹🇼Taiwan
- RegulationThe Ministry of Transportation proposed revoking driving licences for people who used cannabis abroad, even where it was legal.
🇳🇨New Caledonia
🇳🇨New Caledonia
- RegulationNew Caledonia’s Congress adopted a tropical-hemp strategy, defining hemp as THC ≤ 0.3% and framing it as post-crisis diversification.
🇳🇵Nepal
🇳🇵Nepal
- RegulationTwo subnational governments are moving to reopen regulated cultivation, nearly five decades after Nepal’s 1976 ban.
🇧🇸Bahamas
🇧🇸Bahamas
- RegulationThe Bahamas Cannabis Authority said its licensing platform is finished, covering seed-to-sale tracking and e-prescriptions via Metrc.
🇬🇭Ghana
🇬🇭Ghana
- RegulationProf. Yegandi Alagidede proposed a five-step decriminalisation framework at the Fifth Rastafari Cannabis Conference.
🇿🇼Zimbabwe
🇿🇼Zimbabwe
- MarketIvory Medical began producing CBD active pharmaceutical ingredients at 99.9% potency under Zimbabwe’s beneficiation drive.
🇿🇲Zambia
🇿🇲Zambia
- RegulationThe National Cannabis Co-ordinating Committee will issue hemp licences after the election, with cultivation trials targeted for October 2026.
🇳🇦Namibia
🇳🇦Namibia
- RegulationThe Windhoek High Court set 6 July 2026 for judgment in the Ganja Users of Namibia constitutional challenge.
Hover or tap a market. Its card stays open, so you can follow the sources.
Top lines from the June 2026 edition, each linked to its primary source.
Read the full edition →Method
Most cannabis round-ups are a feed. This is not.
Five places where a monthly round-up and a monthly brief part company.
Most newsletters
The Cannamonitor way
Retrieval
Whatever the feed pushed that week.
420+ sources crawled every month — regulators, journals, filings, trade press, official statistics — each weighted by what it is actually expert in.
The month
Items listed in the order they arrived.
The whole month read first, then hierarchised: trends before items, and the ones that matter identified before anything is placed.
Sources
A rewrite of somebody else's write-up.
The primary document — the filing, the decree, the dataset, the judgment. Never based on secondary reporting.
What counts as news
Every headline treated as a development.
A structured view of what was already settled, so only a genuinely meaningful change registers as news.
Coverage
Alerts, aggregators and a trade newsletter.
Key sources crawled monthly, at the source: regulator, ministry, parliament, and the country's own specialist press in its own language.
Plain EnglishInstitutions and statutes written so an operator in Toronto or Sydney recognises them.
Every figure labelledOne concrete number with its exact referent — never two metrics blended into one.
Process status statedNothing in progress is written as concluded. Authorisation is not launch.
One development, one placeWritten once, where it carries most meaning.
Archive
Every edition since July 2023.
Three years of the global market, month by month — all free to read.
Cannamonitor Essentials
Read the full brief the moment it is written.
The free brief is a summary, sent by email once a month. Essentials is where the full brief lives, together with the platform that produces it: every market tracked continuously, classified and sourced.
The free brief
Freeone email a month
- A summary of every editionby email, once a month
- The public editions on this siteevery one since July 2023
- Sources linked in every edition
The full brief, as soon as it is writtenCountry-by-country market pagesNews between editionsAnalyst datapacks and webinar data
Essentials
€14.2per month, or €142 a year
Everything free, plus
- The full brief the moment it is writtenno waiting for the public edition
- Full country-by-country pagesmarket by market, in the platform
- The complete source library780+ primary-source documents
- News between editionsclassified continuously across 120+ markets
- Every analyst datapackadded as they are published
- Webinars in fulltranscripts and the underlying data
Cannamonitor Essentials
Read it first — and everything behind it.
The brief is the monthly synthesis. Essentials is the machine that produces it: every market tracked continuously, classified and sourced — with each edition in your hands the moment it is written.
The free brief
Freeone email a month
- The monthly briefpublished here, weeks after subscribers get it
- Every edition since July 2023the full public archive
- Sources linked in the post
Country-by-country market pagesNews between editionsAnalyst datapacksWebinar transcripts and data
Essentials
€14.2per month, or €142 a year
Everything free, plus
- Each edition the moment it is writtenweeks before it appears here
- Full country-by-country pagesmarket by market, in the platform
- The complete source library780+ primary-source documents
- News between editionsclassified continuously across 120+ markets
- Every analyst datapackadded as they are published
- Webinars in fulltranscripts and the underlying data
See it work
What Essentials looks like.
The same markets you read about here, tracked continuously and classified as they happen — with the brief, the datapacks and the source library alongside.
Subscribe
Get the next edition in your inbox.
One email a month with the summary of every market that moved, and the sources attached. It is free, and you can unsubscribe from any edition.
Want the full brief the moment it is written, with the platform behind it? See Essentials →
Subscribe
Get the next edition in your inbox.
One email a month: every market that moved, with the sources attached. Free, and you can unsubscribe from any edition.
Want it weeks earlier, in full, with the platform behind it? See Essentials →
The Cannamonitor Monthly Brief
Free. One email a month. Unsubscribe from any edition.